Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy.
cognitive impairment
multiple sclerosis
progressive multifocal leukoencephalopathy
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
17 Apr 2022
17 Apr 2022
Historique:
received:
30
03
2022
revised:
15
04
2022
accepted:
16
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Progressive multifocal leukoencephalopathy (PML) is a viral disease characterized by progressive damage or inflammation of the cerebral white matter that can be encountered in patients with multiple sclerosis (MS). There are cases of PML caused by pharmacological agents including natalizumab. Therefore, in patients treated with this drug, early identification of PML allows changes in the treatment plan, reducing the risks of morbidity and mortality. We reported the case of a 57-year-old female diagnosed with relapsing-remitting MS, who presented with PML related to natalizumab. The patient presented with change in behavioral, radiological abnormalities in the left parieto-temporal lobes. We described the longitudinal course of PML, from the diagnosis until the patient's death, documenting the progressive deterioration of her cognitive functioning, supported by changes on sequential brain scans and neurophysiological data. The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.
Sections du résumé
BACKGROUND
BACKGROUND
Progressive multifocal leukoencephalopathy (PML) is a viral disease characterized by progressive damage or inflammation of the cerebral white matter that can be encountered in patients with multiple sclerosis (MS). There are cases of PML caused by pharmacological agents including natalizumab. Therefore, in patients treated with this drug, early identification of PML allows changes in the treatment plan, reducing the risks of morbidity and mortality.
CASE PRESENTATION
METHODS
We reported the case of a 57-year-old female diagnosed with relapsing-remitting MS, who presented with PML related to natalizumab. The patient presented with change in behavioral, radiological abnormalities in the left parieto-temporal lobes. We described the longitudinal course of PML, from the diagnosis until the patient's death, documenting the progressive deterioration of her cognitive functioning, supported by changes on sequential brain scans and neurophysiological data.
CONCLUSION
CONCLUSIONS
The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.
Identifiants
pubmed: 35454389
pii: medicina58040551
doi: 10.3390/medicina58040551
pmc: PMC9025511
pii:
doi:
Substances chimiques
Immunologic Factors
0
Natalizumab
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Références
Mult Scler Int. 2015;2015:809252
pubmed: 26483978
Neurotherapeutics. 2017 Oct;14(4):961-973
pubmed: 28913726
Front Hum Neurosci. 2016 Jun 08;10:282
pubmed: 27375468
Lancet Neurol. 2008 Dec;7(12):1139-51
pubmed: 19007738
Ther Adv Neurol Disord. 2015 Nov;8(6):255-73
pubmed: 26600871
N Engl J Med. 2005 Jul 28;353(4):369-74
pubmed: 15947079
Lancet Neurol. 2017 Nov;16(11):925-933
pubmed: 28969984
Eur J Neurol. 2021 Mar;28(3):921-927
pubmed: 33085811
Intern Med. 2017;56(10):1231-1234
pubmed: 28502942
Ann Clin Transl Neurol. 2014 Oct;1(10):755-64
pubmed: 25493267
Am J Case Rep. 2019 Jan 24;20:101-105
pubmed: 30674865
Lancet Neurol. 2010 Apr;9(4):438-46
pubmed: 20298967
Neurology. 2018 Feb 6;90(6):278-288
pubmed: 29343470
Lancet Neurol. 2020 Oct;19(10):860-871
pubmed: 32949546
J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1068-74
pubmed: 23606731
Neurology. 2018 May 15;90(20):e1815-e1821
pubmed: 29669908
Cleve Clin J Med. 2011 Nov;78 Suppl 2:S8-12
pubmed: 22123935
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
J Neurovirol. 2015 Dec;21(6):702-5
pubmed: 26501778
Egypt J Neurol Psychiatr Neurosurg. 2021;57(1):7
pubmed: 33437143
Case Rep Neurol. 2022 Feb 7;14(1):38-43
pubmed: 35350291
Lancet Neurol. 2018 May;17(5):467-480
pubmed: 29656742
Mult Scler Relat Disord. 2017 Feb;12:59-63
pubmed: 28283109
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):224-6
pubmed: 25628377
Radiology. 2016 Mar;278(3):863-72
pubmed: 26436861